Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.2015020208PMID 26567242PMCID PMC4884104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cathepsin S-Dependent Protease-Activated Receptor-2 Activation: A New Mechanism of Endothelial Dysfunction.

  2016cited by this paper
• Extracellular histones in tissue injury and inflammation

  2014cited by this paper
• Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.

  2014cited by this paper
• Functional role of protease activated receptors in vascular biology.

  2014cited by this paper
• Cathepsin S Signals via PAR2 and Generates a Novel Tethered Ligand Receptor Agonist

  2014cited by this paper
• Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes

  2014cited by this paper
• The Endothelium in Diabetic Nephropathy

  2014cited by this paper
• Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion.

  2013cited by this paper
• Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming

  2013cited by this paper
• The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration.

  2013cited by this paper
• Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.

  2013cited by this paper
• Elastin Degradation Is Associated With Progressive Aortic Stiffening and All-Cause Mortality in Predialysis Chronic Kidney Disease

  2012cited by this paper
• Association Between Serum Cathepsin S and Mortality in Older Adults

  2012cited by this paper
• Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy

  2012cited by this paper
• Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation.

  2012cited by this paper
• Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice

  2012cited by this paper
• Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.

  2012cited by this paper
• Serum Cathepsin S Is Associated With Decreased Insulin Sensitivity and the Development of Type 2 Diabetes in a Community-Based Cohort of Elderly Men

  2012cited by this paper
• Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.

  2012cited by this paper
• The endothelium in diabetic nephropathy.

  2012cited by this paper
• Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.

  2012cited by this paper
• Endothelial dysfunction as a potential contributor in diabetic nephropathy

  2011cited by this paper
• Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications.

  2011cited by this paper
• Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease.

  2011cited by this paper
• Association between serum cathepsin S and mortality in older adults.

  2011cited by this paper
• Cardiovascular , Pulmonary and Renal Pathology Late Onset of Ccl 2 Blockade with the Spiegelmer mNOX-E 36 – 3 PEG Prevents Glomerulosclerosis and Improves Glomerular Filtration Rate in db / db Mice

  2010cited by this paper
• Cathepsins and cystatin C in atherosclerosis and obesity.

  2010cited by this paper
• Systematic Analysis of a Novel Human Renal Glomerulus-Enriched Gene Expression Dataset

  2010cited by this paper
• Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice.

  2010cited by this paper
• Leukocyte Cathepsin S Is a Potent Regulator of Both Cell and Matrix Turnover in Advanced Atherosclerosis

  2009cited by this paper
• Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease

  2009cited by this paper
• Mechanisms of endothelial dysfunction, injury, and death.

  2009cited by this paper
• Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway.

  2009cited by this paper
• Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

  2009cited by this paper
• Resident Dendritic Cells Prevent Postischemic Acute Renal Failure by Help of Single Ig IL-1 Receptor-Related Protein1

  2009cited by this paper
• Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.

  2008cited by this paper
• From Fibrosis to Sclerosis

  2008cited by this paper
• Role of remission clinics in the longitudinal treatment of CKD.

  2008cited by this paper
• Cathepsin cysteine proteases in cardiovascular disease

  2007cited by this paper
• Podocytes in culture: past, present, and future.

  2007cited by this paper
• Different roles of TiR8/Sigirr on toll-like receptor signaling in intrarenal antigen-presenting cells and tubular epithelial cells.

  2007cited by this paper
• Leukocyte recruitment and vascular injury in diabetic nephropathy.

  2006cited by this paper
• Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue

  2006cited by this paper
• Increased serum cathepsin S in patients with atherosclerosis and diabetes.

  2006cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Functional consequences of integrin-linked kinase activation in podocyte damage.

  2005cited by this paper
• Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease.

  2005cited by this paper
• Lysosomal Cysteine Proteases in Atherosclerosis

  2004cited by this paper
• Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth

  2003cited by this paper
• Literature alert

  2003cited by this paper
• Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice.

  2003cited by this paper
• Albuminuria and vascular damage--the vicious twins.

  2003cited by this paper
• An in-depth analysis of electric cell-substrate impedance sensing to study the attachment and spreading of mammalian cells.

  2002cited by this paper
• Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

  2002cited by this paper
• Cystatin C deficiency in human atherosclerosis and aortic aneurysms.

  1999cited by this paper
• The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature.

  1997cited by this paper

• Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy.

  2026cites this paper
• Multi-omics analysis reveals that low cathepsin S expression aggravates sepsis progression and worse prognosis via inducing monocyte polarization

  2025cites this paper
• The pH-Dependent Specificity of Cathepsin S and Its Implications for Inflammatory Communications and Disease

  2025cites this paper
• Proteomic and metabolomic profiling reveals the underlying molecular mechanisms in modified alternate-day fasting-mediated protection against Diabetic kidney disease

  2025cites this paper
• The Many Faces of Protease-Activated Receptor 2 in Kidney Injury

  2025cites this paper
• Evaluation of the pharmacological cathepsin S inhibitor LY3000328 on autoimmune diabetes in mice.

  2025cites this paper
• Integrative Proteome- and Phenome-Wide Assessment Uncovers Causal Protein Drivers and Drug Targets for Heterogeneous Kidney Diseases

  2025cites this paper
• Integrating multi-omic Mendelian randomization, microarray, single-cell RNA sequencing, and spatial RNA sequencing to identify potential therapeutic targets for vitiligo.

  2025cites this paper
• Cathepsin S: molecular mechanisms in inflammatory and immunological processes.

  2025cites this paper
• CST3 alleviates retinal vascular leakage by regulating the Rap1 signaling pathway.

  2024cites this paper
• Identification of co-expressed central genes and transcription factors in acute myocardial infarction and diabetic nephropathy

  2024cites this paper
• Proteomics-Based Identification of Potential Therapeutic Targets of Artesunate in a Lupus Nephritis MRL/lpr Mouse Model.

  2024cites this paper
• Profiling of insulin-resistant kidney models and human biopsies reveals common and cell-type-specific mechanisms underpinning Diabetic Kidney Disease

  2024cites this paper
• Pharmacological inhibition of cathepsin S and of NSPs-AAP-1 (a novel, alternative protease driving the activation of neutrophil serine proteases).

  2024cites this paper
• The renal resistive index is associated with microvascular remodeling in patients with severe obesity

  2023cites this paper
• Protease-activated receptors in kidney diseases: A comprehensive review of pathological roles, therapeutic outcomes and challenges.

  2023cites this paper
• The cathepsin-S/protease-activated receptor-(PAR)-2 axis drives chronic allograft vasculopathy and is a molecular target for therapeutic intervention.

  2023cites this paper
• Identification of immune-related molecular clusters and diagnostic markers in chronic kidney disease based on cluster analysis

  2023cites this paper
• Targeted deletion of von-Hippel-Lindau in the proximal tubule conditions the kidney against early diabetic kidney disease

  2023cites this paper
• Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: From fundamental research to therapy.

  2023cites this paper
• Diagnostic value of serum cathepsin S in type 2 diabetic kidney disease

  2023influential citation
• Porphyromonas gingivalis outer membrane vesicles exacerbate retinal microvascular endothelial cell dysfunction in diabetic retinopathy

  2023cites this paper
• The consequence of endothelial remodelling on the blood spinal cord barrier and nociception

  2022cites this paper
• Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos.

  2022cites this paper
• Progressively Decreased HCN1 Channels Results in Cone Morphological Defects in Diabetic Retinopathy

  2022cites this paper
• Exploring the pathogenesis of diabetic kidney disease by microarray data analysis

  2022cites this paper
• Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential.

  2022cites this paper
• Role of cathepsin K in the expression of mechanical hypersensitivity following intra-plantar inflammation

  2022cites this paper
• Proteome Changes Associated with the VEGFR Pathway and Immune System in Diabetic Macular Edema Patients at Different Diabetic Retinopathy Stages

  2022cites this paper
• Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome.

  2022cites this paper
• Oxidative stress and proteolysis system in type 2 diabetes

  2022cites this paper
• The Clinical Significance and Potential Role of Cathepsin S in IgA Nephropathy

  2021cites this paper
• Heart failure in diabetes.

  2021cites this paper
• Relationship between lysosomal dyshomeostasis and progression of diabetic kidney disease

  2021cites this paper
• Lipopeptide Pepducins as Therapeutic Agents.

  2021cites this paper
• WITHDRAWN: Staphylococcus aureus-serine protease-like protein B (SplB) activates PAR2 and induces endothelial barrier dysfunction

  2021cites this paper
• Diabetic Endotheliopathy: RNA-Binding Proteins as New Therapeutic Targets.

  2020cites this paper
• Melatonin attenuates epidermal growth factor‐induced cathepsin S expression in ARPE‐19 cells: Implications for proliferative vitreoretinopathy

  2020cites this paper
• Cysteinyl cathepsins in cardiovascular diseases.

  2020cites this paper
• Retinal endothelial cell phenotypic modifications during experimental autoimmune uveitis: a transcriptomic approach

  2020cites this paper
• Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease.

  2020cites this paper
• Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics

  2020cites this paper
• Cathepsin S and Protease-Activated Receptor-2 Drive Alloimmunity and Immune Regulation in Kidney Allograft Rejection

  2020cites this paper
• Decreased serum cathepsin S levels in patients with systemic sclerosis‐associated interstitial lung disease

  2020cites this paper
• New Trends in Vascular Inflammation Research: From Biology to Therapy

  2019cites this paper
• Glomerular Injury Is Exacerbated in Lupus-Prone MRL/lpr Mice Treated with a Protease-Activated Receptor 2 Antagonist.

  2019cites this paper
• Electric cell-substrate impedance sensing in kidney research.

  2019cites this paper
• The cysteine protease legumain - from cell biology to cardiovascular disease

  2019cites this paper
• Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice

  2019cites this paper
• Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome

  2019cites this paper
• Inhibition of Cathepsin S Reduces Lacrimal Gland Inflammation and Increases Tear Flow in a Mouse Model of Sjögren’s Syndrome

  2019cites this paper
• Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes

  2019cites this paper
• Update on protease‐activated receptor 2 in cutaneous barrier, differentiation, tumorigenesis and pigmentation, and its role in related dermatologic diseases

  2019cites this paper
• Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases

  2019cites this paper
• Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury

  2019cites this paper
• Alteration in endothelial permeability occurs in response to the activation of PAR2 by factor Xa but not directly by the TF-factor VIIa complex.

  2019cites this paper
• Targeting of cathepsin S reduces cystic fibrosis-like lung disease

  2019cites this paper
• Cathepsin S Alters the Expression of Pro-Inflammatory Cytokines and MMP-9, Partially through Protease—Activated Receptor-2, in Human Corneal Epithelial Cells

  2018cites this paper
• Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease

  2018cites this paper
• The diabetes pandemic suggests unmet needs for ‘CKD with diabetes’ in addition to ‘diabetic nephropathy’—implications for pre-clinical research and drug testing

  2018cites this paper
• Coagulation Signalling and Metabolic Disorders: Lessons Learned from Animal Models

  2018cites this paper
• Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model

  2018cites this paper
• 3 Chapter 3 Protease activated receptor 2 in diabetic nephropathy : a double edged sword .

  2018cites this paper
• Protease-activated receptors in diabetic nephropathy and renal fibrosis

  2018cites this paper
• Circulating cathepsin-S levels correlate with GFR decline and sTNFR1 and sTNFR2 levels in mice and humans

  2017cites this paper
• Protease Cathepsins in Cardiomyopathy: From Mechanism to Intervention

  2017cites this paper
• Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury

  2017cites this paper
• Protease-activated receptor 2 exacerbates adenine-induced renal tubulointerstitial injury in mice.

  2017cites this paper
• Vascular endothelium in diabetes.

  2017cites this paper
• Protease activated receptor 2 in diabetic nephropathy: a double edged sword.

  2017cites this paper
• The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease

  2017cites this paper
• Endothelial colony forming cells (ECFCs) and biomaterials : a synergy for next-generation cardiovascular implants

  2016cites this paper
• Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis

  2016cites this paper
• Cathepsin L is crucial for the development of early experimental diabetic nephropathy.

  2016cites this paper
• Cathepsins are potential therapeutic targets in kidney disease.

  2016cites this paper
• Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy

  2016cites this paper
• Cathepsin S-Dependent Protease-Activated Receptor-2 Activation: A New Mechanism of Endothelial Dysfunction.

  2016cites this paper